Philips reiterates FY25 outlook following steady Q3 performance

Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Pfizer reports Q3 vaccine sales decline amid challenging US market conditions

Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion

Amgen confident in US biosimilar market’s strength as sales surge 52%

Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies

Sovato secures series B funding to advance remote robotic surgery platform

The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies

Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial

VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.